相关实验视频
Updated: Jul 12, 2025

07:20
Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
Published on: January 31, 2025
516
佩戈扎费明是代谢障碍的潜在主治疗调节剂:一篇评论
Nadian N Bailey1, Stephen J Peterson1,2, Manish A Parikh1,2
1From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY.
Cardiology in review
|October 27, 2023
概括
用纤维细胞生长因子21 (FGF21) 治疗的 Pegozafermin 通过减少甘油三和肝脂肪,显著改善了代谢健康. 这种新的治疗方法对诸如非酒精性脂肪性肝病等疾病具有前景.
科学领域:
- 代谢性疾病研究研究.
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 纤维细胞生长因子21 (FGF21) 是一种具有短半衰期的关键代谢调节剂.
- 代谢并发症,如严重的高甘油三血症和非酒精性脂肪肝 (NAFLD) 需要有效的治疗.
- 佩戈扎费明 (PGZ) 是一种经过修改的FGF21具有延长半衰期,旨在改善代谢功能.
研究的目的:
- 评估Pegozafermin (PGZ) 在代谢功能障碍患者的疗效和安全性.
- 评估PGZ对关键代谢参数的影响,包括甘油三,胰岛素敏感性和肝脂肪.
主要方法:
- ENTRIGUE试验是一项2期临床研究,研究了PGZ的作用.
- 与安慰剂相比,参与者接受了PGZ,一种糖化FGF21模拟剂.
- 关键的代谢标志物和肝脏参数被监测.
主要成果:
- 与安慰剂相比,PGZ显示甘油三水平降低了57%.
- 在PGZ治疗下,肝脏脂肪酸症的减少率为45%.
- 胰岛素敏感性,非HDL-C和阿波利波蛋白B-100的改善被注意到.
结论:
- 佩戈扎费明在治疗严重的高甘油三血症和非酒精性脂肪肝炎 (NASH) 中具有显著的潜力.
- 它的延长半衰期和作用机制为代谢障碍提供了有前途的治疗方法.
- 需要进一步的临床试验来证实这些发现.
相关概念视频
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Regulation of Metabolism
9.5K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.5K
G Protein-coupled Receptors
12.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.2K
Allosteric Regulation
58.1K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.1K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334

